China Agent for Overseas Registrants: Qualification, Authorisation and Liability

1. Key takeaways

China’s import pathway treats the in-country agent as a structural requirement, not a commercial convenience: it is the entity through which the regulator reaches an overseas manufacturer.

• The agent is mandatory, not optional. Article 14, paragraph 2 of the Medical Device Registration and Filing Measures uses the wording shall designate. A China-incorporated enterprise legal person designated by the overseas applicant or filer is a precondition for acceptance of import registration and filing.
• The single hard test is the phrase enterprise legal person within China. Natural persons, individual businesses, the overseas manufacturer itself and China representative offices all fail it. A branch office is a non-legal-person division and is likewise not accepted.
• The agent carries two layers of statutory duty. It handles registration and filing, and assists the holder with the Article 20, paragraph 1 obligations and corresponding liability.
• Agent name and domicile are filing items, not particulars printed on the certificate. A change must be filed within 30 days of the date of change under Article 79; variation registration does not apply.
• Instructions and labels must state the agent’s details. Article 10(2) and Article 13(2) of former CFDA Order No. 6 require the agent’s name, domicile and contact details, with the Chinese text prevailing.
• Late filing carries an express penalty. Article 107 requires correction within a set period and, where that is not done, a fine of CNY 10,000 to CNY 30,000.

In our assessment, the system is built around reachability and accountability. The exposure is less the wording of the authorisation than the response when a lapsed authorisation, relocated office or departing contact breaks the chain.

2. Legal basis

Three tiers apply: a regulation creating the obligation, rules prescribing procedure, and labelling provisions governing disclosure.

Medical Device Supervision and Administration Regulations (State Council Order No. 739, promulgated 9 February 2021, effective 1 June 2021)

• Article 20, paragraph 2: the designated China entity shall assist the overseas holder or filer with the paragraph 1 obligations.
• Article 15, paragraph 2 and Article 16, paragraph 2: Class I filers and Class II and III applicants submit materials to NMPA through that entity.
• Article 21: substantive changes require variation registration; other changes are filed or reported.

Medical Device Registration and Filing Measures (SAMR Order No. 47, promulgated 26 August 2021, effective 1 October 2021)

• Article 8, paragraphs 5 and 6: Class I import filing is submitted by the designated entity; Class II and III imports are certificated by NMPA after review and approval.
• Article 14, paragraph 2: the overseas applicant or filer shall designate an enterprise legal person within China as agent, which handles registration and filing, assists with the Article 20, paragraph 1 obligations and helps implement legal liability.
• Article 79: substantive changes go to variation registration; other changes must be filed with the original registering authority within 30 days. The holder’s and the agent’s name and domicile are filing items.
• Article 107: failure to file leads to an order to correct and, on expiry, a fine of CNY 10,000 to CNY 30,000.

Provisions on the Administration of Medical Device Instructions and Labels (former CFDA Order No. 6, promulgated 30 July 2014, effective 1 October 2014)

• Article 10(2): imported devices shall also state the agent’s name, domicile and contact details.
• Article 13(2): the label of an imported device shall state the same details.

Practical estimate. Article 20, paragraph 1 lists five holder obligations: quality system maintenance, adverse-event monitoring and reporting, recall, instructions and label management, and periodic self-inspection. Validity period, renewal, file handover and ownership of regulatory accounts are not harmonised, so the parties must agree them and retain the record.

3. Expert insights

Eligibility turns on organisational form, not commercial substance. Article 14, paragraph 2 and Articles 15 and 16 use identical wording, an enterprise legal person within China, which imposes a territorial and an organisational test.

The logic is capacity to bear liability independently: a representative office’s liability sits with the overseas parent, so enforcement travels abroad, defeating domestic accountability.

Statutory duties cannot be narrowed by contract. The statutory layer covers registration and filing, which is procedural, and assistance with the holder’s obligations and liability, which is substantive. The contractual layer covers delegated matters: adverse-event information, recalls, UDI data, Chinese instructions and distributor notification. It may add to the statutory layer but not subtract from it, so a clause saying the agent merely submits documents does not bind the regulator.

An over-broad mandate is equally risky: if quality system operation or release decisions are written in, the holder cannot escape responsibility for a defective product by citing delegation.

Choosing the wrong procedure loses the deadline. Article 79 creates three channels, and the common error is treating an agent change as variation registration.

The cost is twofold: variation registration takes longer, and the clock runs from the date of change, so a return from the wrong channel arrives late. Office relocation is the usual trigger.

One agent change triggers a chain most companies only half complete. Agent details appear on six carriers: the certificate, the instructions under Article 10(2), the smallest sales unit label under Article 13(2), unsold printed Chinese stock, the UDI record under Article 15 of the system rules, and distribution channels with hospital files and online sales pages. Most treat the first as closure; the fourth and sixth are most often missed, the sixth feeding the consistency rules of the Medical Device Online Sales Quality Management Specification (Announcement No. 46 of 2025, effective 1 October 2025).

4. Practical recommendations

• Verify eligibility before signing. Check the licence for scope, continuing status and legal representative, confirm the applicant type is enterprise legal person, and retain a sealed copy.
• Draft the authorisation in two parts. Track the Article 14, paragraph 2 duties first, then list delegated matters, response times and contacts, stating that the authorisation does not affect the holder’s own obligations.
• List the filing triggers and assign owners. For name, domicile, legal representative and contact changes, specify who files and within how many working days.
• Run a 30-day countdown ledger. Work back from the date of change, reserve preparation time, and aim to file within 20 days (practical estimate).
• Plan the instruction and label revision in parallel. Start it in the filing month so product on sale does not carry the old details.
• Include termination terms in the agency agreement. Cover file handover, transfer of the submission account, treatment of stock on the market and open adverse-event and recall matters.

5. Verification checklist

• □ The agent is an enterprise legal person within China with a valid licence, not listed as abnormal.
• □ The authorisation is signed by the legal representative or a duly authorised signatory whose authority is verifiable.
• □ It covers both duties: registration and filing, and assistance with Article 20, paragraph 1 obligations and liability.
• □ A separate section sets out delegated duties (adverse events, recalls, UDI) with time limits.
• □ No clause relieves the holder of a statutory obligation or transfers quality system responsibility.
• □ The authorisation covers the certificate’s life, with a renewal mechanism and warning date.
• □ The agent’s name and domicile are registered as filing items and match the certificate.
• □ Any change of agent name or domicile was filed within 30 days of the change.
• □ The Chinese instructions state the agent’s name, domicile and contact details (Order No. 6, Article 10(2)).
• □ The smallest sales unit label states the same details (Article 13(2)), Chinese text prevailing.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Chinese market. Our team acts as the in-China registration agent, coordinates import agent and distributor arrangements, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com